Dr. Luc Marengère

About

Dr. Luc Marengère joined TVM Partners in 2012 and serves as a Managing Partner. He is responsible for TVM Partners' overall investment strategy and global fund operations. Luc has over 25 years of venture capital experience and is a key driver of the investment strategy for TVM LSI I and TVM LSI II Funds. He holds board positions at Panthera Dental, Egg Medical, Kent Imaging, Emovi, Access Vascular, Vespina, Occellaris and Auricula. He previously served on the boards of NASDAQ-listed Acer Therapeutics (sold to Zevra Therapeutics) and Colucid Pharma Inc. (sold to Eli Lilly for US$960M), as well as privately held Aurka Pharma Inc. (sold to Eli Lilly for US$575M) and Acanthas Pharma (sold to Eli Lilly for US$430M). Before TVM, Luc was a Managing Partner at VG Partners, where he founded the life science investment practice and led deals including Cytochroma Inc. (sold to Opko for US$400M), VisualSonics (sold to Sonosite for US$75M), CITA Neuropharma (sold to Vernalis Plc for US$85M), and Trillium Therapeutics (sold to Pfizer for US$2.2B). Earlier in his career, he focused on venture investments at Caisse De Depot (CDP), MDS Capital, and MedTech Partners. Before venture capital, he conducted research in immunology and oncology at Amgen. Luc holds a Ph.D. from the University of Toronto (Medical Biophysics and Molecular Genetics), a Master’s degree from Queen’s University (Biochemistry), and a Bachelor’s degree from the University of Ottawa (Biochemistry, Magna Cum Laude).